Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05389267 · ClinicalTrials.gov registry record · Phase 1
Safety Assessment of T4090 Eye Drops in Ocular Hypertensive or Glaucomatous Patients.
A Phase 1 study of Glaucoma and Ocular Hypertension, sponsored by Laboratoires Thea.
- Active
- Registry status
- Phase 1
- Development phase
- 120
- Enrollment target
- 1
- Study location
NCT05389267 is a Phase 1 study of Glaucoma and Ocular Hypertension that is active but no longer recruiting, run by Laboratoires Thea. The registered enrollment target is 120 participants, below the 909-participant average among 92 other Glaucoma trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05389267, a Phase 1 study of Glaucoma and Ocular Hypertension, is active but no longer recruiting, sponsored by Laboratoires Thea.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 120 participants
- Enrollment target
- 1
- Study location
Study Summary
The study purpose is to evaluate the safety of T4090.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Kinezodianone R hydrochloride
Study Locations (1)
California
- Dr EL-HARAZI - Glendale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2022-07-05 |
| Est. Completion | 2024-12-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05389267
The ClinicalTrials.gov registry entry for NCT05389267 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 909-participant average among 92 other Glaucoma trials with a reported enrollment target (87% lower). The listed sponsor is Laboratoires Thea, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Glaucoma appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05389267 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT05389267 about?
NCT05389267 is a clinical study titled "Safety Assessment of T4090 Eye Drops in Ocular Hypertensive or Glaucomatous Patients.". The study purpose is to evaluate the safety of T4090.
What is the current status of trial NCT05389267?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 120 participants. The study started on 2022-07-05. Estimated completion is 2024-12-31.
What conditions does trial NCT05389267 study?
This clinical trial studies the following conditions: Glaucoma, Ocular Hypertension.
What interventions are being tested in trial NCT05389267?
The interventions under investigation include: Placebo (DRUG), Kinezodianone R hydrochloride (DRUG).
Who is sponsoring clinical trial NCT05389267?
This trial is sponsored by Laboratoires Thea, which has 11 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05389267 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glaucoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Topical Insulin for Glaucoma
RECRUITING · Phase 1
-
Evaluation of the Bimatoprost Implant System Used in Combination With the SpyGlass Intraocular Lens Compared to Timolol Ophthalmic Solution
ACTIVE NOT RECRUITING · Phase 1
-
A Dose-Escalation Study Designed to Evaluate the Tolerability, Safety, Pharmacokinetics (PK), and Efficacy of Chronic Topical Ocular Application of INO-8875 in Adults With Ocular Hypertension or Primary Open-Angle Glaucoma
COMPLETED · Phase 1
-
Therapeutic Equivalence Study of Generic Brinzolamide vs Azopt
COMPLETED · Phase 1
-
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO5093151 in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT).
COMPLETED · Phase 1
-
Efficacy, Tolerability and Safety of RKI983 (0.05% & 0.10%) vs Xalatan in Patients With POAG or Ocular Hypertension
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.